Attorney and former in-house general counsel, Sarah Hibbard, helps technology, life sciences, and digital health companies create a strong legal foundation and position themselves for growth on the journey from research to commercial success, drawing on in-house start-up and multibillion-dollar company experience.
Her focus includes general corporate governance, private debt and equity financings, and mergers and acquisitions, as well as structuring and negotiating intellectual property and commercial transactions such as licensing and tech transfers, collaborations, pre-clinical and clinical research, research and development activities, and manufacturing.
Sarah also helps boards and C-suites balance corporate governance and risk, steward and deploy capital, and carefully navigate the interplay between stock performance, legal compliance, litigation, and operational continuity. In addition, she advises companies in dealings with government agencies, legislators, and other stakeholders.
Prior to joining Snell & Wilmer, Sarah was general counsel for a San Diego-based biotechnology company operating in the oncology space. Her experience includes biotech, medical device, and aesthetics, as well as hardware and XaaS technologies.